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Osteoclasts, the cells that degrade bone, differentiate from bone marrow-derived myeloid precursors.
Recent work by Ishii et al. shows that sphingosine-1 phosphate in blood attracts osteoclast precursors
into the bloodstream to keep them away from bone surfaces. These findings point to a novel mechanism
to inhibit bone degradation and prevent bone loss.Bone strength is maintained by bone
remodeling, which starts with osteoclasts
removing weak or damaged bone. The
resulting microscopic trenches on the
bone surface are filled with the new bone
laid down by osteoblasts (Figure 1). Oste-
oclasts are multinucleated cells, which
originate from the fusion of myeloid bone
marrow osteoclast precursors (OCPs) in
response to cytokines such as RANKL
and other influences. Osteoblasts are
mesenchymal cells derived from precur-
sors in the bone marrow stroma. There
are over one million bone remodeling
trenches (called BMUs) in the normal adult
skeleton. However, like skin, hair, and
muscles, bones get thinner and weaker
with aging. For example, BMU numbers
increase after menopause when osteo-
clasts dig deeper trenches than normal
and osteoblasts do not fill them in
completely, leading eventually to osteo-
porosis.
Understanding of the molecular mecha-
nisms that regulate osteoclast and osteo-
blast formation has advanced rapidly in
recent years. For example, RANKL—
which is expressed by osteoblasts, T and
B cells, or inflamed rheumatoid joints—is
known to activate NF-kB and NFATc1 in
OCPs to induce their differentiation
(reviewed in Takayanagi, 2007 and Boyce
and Xing, 2008). Conversely, osteoprote-
gerin (OPG) is also expressed by osteo-
blastic and B cells, but binds to and
prevents RANKL from interacting with its
receptor, thus limiting osteoclast formation
and bone degradation. OPG expression is
regulated by many of the factors that regu-
late RANKL expression. What’s more,
similarly to RANKL, it has important func-
tions in other organ systems (reviewed inBoyce and Xing, 2008 and Kollet et al.,
2007). It was known for many years that
hormones and cytokines regulate bone
remodeling mainly through osteoblasts
regulating osteoclast formation. Given the
close interaction between these two cell
types in bone, it was not too surprising
that osteoclastic cells eventually were
found to regulate osteoblast formation
(reviewed in Kollet et al., 2007). However,
it was not anticipated that leptin regulates
bone mass through a hypothalamic
neuronal relay (Shi et al., 2008), that bone
would actas an endocrine organ regulating
energy metabolism through osteoblast
secretion of osteocalcin (Hinoi et al.,
2008), or that enterochromaffin cells in
the duodenum would negatively regulate
bone formation by secreting serotonin in
response to signaling through the lipid
receptor LRP5 (Yadav et al., 2008).
Another unexpected finding was that oste-
oblasts regulate egress of hematopoietic
precursors, including OCPs, from the
bone marrow into the blood. Osteoclasts
also participate in this egress, further
emphasizing their close interaction with
osteoblasts (reviewed inKollet et al., 2007).
In order to understand osteoclast
migration, many researchers have turned
to chemokines that regulate related hema-
topoietic lineages (reviewed in Kollet et al.,
2007). On the other hand, sphingosine-1
phosphate (S1P) and its receptors control
the egress of thymocytes from the
thymus, trafficking of lymphocytes in
secondary lymphoid organs, and migra-
tion of B cells into splenic follicles (re-
viewed by Rivera et al., 2008). Since Ishii
et al. (2009) knew that OCPs also circulate
in blood, they chose to study the role of
S1P and S1P receptors in this process.Developmental Cell 1They found that OCPs highly expressed
S1PR1, which decreased in response to
RANKL. In contrast, osteoclasts on bone
surfaces had very low expression of
S1PR1. OCPs showed a chemotactic
response to S1P in vitro, which was atten-
uated by RANKL. They then used two-
photon imaging to confirm that OCPs
migrated in vivo in murine calvarial bone
marrow in response to systemic adminis-
tration of a S1PR1 agonist and that some
of these cells entered the bloodstream.
This treatment increased numbers of
OCPs in the blood and decreased them
in bone marrow. The authors generated
mice with OCP-specific deletion of
S1PR1 and found they were osteoporotic,
with increased numbers of osteoclasts
attached to their bone surfaces. S1P did
not affect RANKL-induced OCP differenti-
ation. So, loss of S1PR1 appeared to alter
the chemotactic behavior of OCPs, rather
than their differentiation or the bone-
degrading activity of osteoclasts. To
explore this possibility further, the authors
examined the effects of FTY720, a S1PR1
agonist used as an immunosuppressant
to prevent lymphocyte egress from lymph
nodes, in a murine ovariectomy model of
postmenopausal osteoporosis. They
found that FTY720 prevented ovariec-
tomy-induced bone loss by decreasing
osteoclast attachment to bone surfaces.
OCP numbers were increased in the blood
and decreased in the marrow of the ovari-
ectomized mice treated with FTY720,
which did not affect RANKL, OPG, or
estrogen levels.
These new findings support a role for
S1P in keeping OCPs in the blood and
away from bone surfaces to limit bone
loss (Figure 1). This represents a novel6, March 17, 2009 ª2009 Elsevier Inc. 323
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is different from the actions of established
drugs, which limit osteoclast formation,
activity, lifespan, or some combination of
the three. This raises the question of
what attracts OCPs back from the blood
to the marrow and to bone surfaces that
are to be degraded. SDF-1 is a candidate
and an established chemoattractant
protein (reviewed in Kollet et al., 2007).
A further piece of the S1P puzzle is the
recent report that osteoclasts produce
S1P during their differentiation. S1P also
promotes osteoblast precursor recruit-
ment to BMUs and promotes survival of
mature osteoblasts (Pederson et al.,
2008). Thus, osteoclasts may recruit os-
teoprogenitors to sites of bone resorption
and promote mature osteoblast survival
by secreting S1P (Figure 1). If mature oste-
oclasts produce S1P, do they also recruit
OCPs to themselves to increase their
size and nuclear number? Recent studies
have reported that the autonomic nervous
system regulates SDF-1 marrow levels
(Katayama et al., 2006). Is there interaction
between circulating S1P and the auto-
nomic nervous system for the regulation
of osteoclast precursor mobilization?
How all of these new data fit into a compre-
hensive integrated system for the regula-
tion of bone and body mass will require
further study as well as confirmation that
they also exist in humans. They do indicate
that bone remodeling doesn’t just renew
worn-out bone.
These new studies raise several other
questions. Will S1PR1 agonists prevent
Figure 1. Proposed Roles for Sphingosine-1 Phosphate in Bone Remodeling
In the normal state (left-hand panel), S1P levels are higher in blood than in tissues. S1P attracts OCPs from
the bone marrow into the bloodstream, protecting bone surfaces. During bone remodeling (right-hand
panel), an osteoclast (arrow) has formed a trench along the bone surface. Osteoclasts produce S1P
and attract osteoblast precursors that differentiate and fill in the trench with new bone. Osteoclast S1P
may also attract OCPs from the blood to fuse with them and increase their size. However, osteoclasts
express S1PR1 at low levels, so presumably this receptor is not involved in the fusion process.
Osteoblasts are indicated by arrowheads, and hypothetical S1P levels by green dots. BM, bone marrow;
BV, blood vessel; B, bone.324 Developmental Cell 16, March 17, 2009 ª2009 Elsevier Inc.bone loss in patients with postmeno-
pausal osteoporosis or rheumatoid
arthritis? What regulates S1P concentra-
tions in blood to mediate OCP egress
from bone marrow, and is it low in patients
with increased bone degradation?
The growing field of osteoimmunology
teaches us that OCPs and osteoclasts
mediate immune responses, similarly to
B and T cells. These latter cells secrete
RANKL to regulate OCP differentiation in
inflammatory bone diseases. Are S1P
blood levels regulated to control lympho-
cyte numbers differentially from those of
OCPs, or are these cell types even more
closely linked than we currently think?
Are these interactions regulated somehow
through an integrated brain, gut, bone
marrow, and bloodstream system? What
will the next surprise be?
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